CLAIMS

What is claimed is:

1. ~~A method for treating moderate to severe chronic hand eczema in a subject in need thereof, which method comprises the step of administering to said subject a therapeutically effective amount~~ Use of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of moderate to severe chronic hand eczema in a subject, wherein a therapeutically effective amount of the medicament is to be administered to said subject in need thereof.

2. The use~~method~~ of claim ~~2~~1, wherein the therapeutically effective amount is selected from the group consisting~~consisint~~ of 50, 100 or 200 mg.

3. The use~~method~~ of claim 2, wherein the therapeutically effective amount is 50 mg.

4. The use~~method~~ of claim 2, wherein the therapeutically effective amount is 100 mg.

5. The use ~~method~~ of claim 2, wherein the therapeutically effective amount is 200 mg.

6. The use~~method~~ of any of claims 1 to 5, wherein the therapeutically effective amount is to be administered QD.

7. The use~~method~~ of any of claims 1 to 6, wherein the N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, or a pharmaceutically acceptable salt thereof is to be administered to said subject for up to 16 weeks.

8. The use~~method~~ of any of claims 1 to 7, wherein the N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, or a pharmaceutically acceptable salt thereof is to be administered to said subject for up to 52 weeks.

9. The use~~method~~ of any of claims 1 to 8, wherein whereby said subject achieves an Investigator Global Assessment (IGA) response score of 0-1 and ≥2 points reduction in score from baseline.

10. The use~~method~~ of claim 9, wherein said subject maintains said IGA response.

11. The use~~method~~ of any of claims 1 to 9, whereby said subject achieves an IGA response score of 0-1 and ≥2 points reduction in score from baseline by Week 16.

12. The use~~method~~ of any of claims 1 to 11, whereby said subject achieves an improvement in Total Lesion Severity Score (TLSS) of at least about 50 to about 70% reduction from baseline TLSS by Week 16.

13. The use~~method~~ of any of claims 1 to 12, whereby said subject achieves a response of at least a 4-point improvement on Worst Itch Numerical Rating Scale (Worst Itch NRS4) by Week 16.

14. The use~~method~~ of any of claims 1 to 13, wherein said subject maintains said improvement in the Worst Itch NRS4 score.

15. The use~~method~~ of any of claims 1 to 14, whereby said subject achieves at least a 20 percent improvement in the Work Productivity and Activity Impairment Questionnaire (WPAI-CHE) Scale by Week 16.

16. The use ~~method~~ of any of claim 15, wherein said subject maintains the improvement in the WPAI-CHE score.

17. The use~~method~~ of any of claims 1 to 16, whereby flare as measured by IGA score is maintained at less than or equal to 3.

18. The use~~method~~ of any of claims 1 to 17, wherein the improvement in response is within 14 days.

19. The use~~method~~ of any of claims 1 to 18, further comprising a co-administration of~~co-administering~~ a topical agent selected from the group consisting of a crisaborole, corticosteroid, a calcineurin inhibitor, pimecrolimus and tacrolimus.

20. The use~~method~~ of claim 19, wherein the topical co-administration is by means of an ointment or cream.

~~21. Use of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of chronic hand eczema according to any of claims 1 to 20.~~